- June 28, 2022
- Newsletter
- 617-430-5616
Menu
Brand Name :
Somatuline Depot, Somatuline Autogel
Synonyms :
lanreotide
Class :
Antineoplastic agents & Somatostatin analog
Brand Name :
Somatuline Depot, Somatuline Autogel
Synonyms :
lanreotide
Class :
Antineoplastic agents & Somatostatin analog
Dosage Forms & Strengths
Solution, Subcutaneous (SC):
120 mg/0.5ml
60 mg/0.2ml
90mg/0.3ml
90
mg
every 4 weeks
3
months
Initial dose
Maintenance dose: based on the clinical response of the patient.
Dose Adjustments
Growth hormone <1mg/ml: 60 mg once every 4 weeks
Growth hormone >1 to 2.5 ng/ml: 90 mg once every 4 weeks
Growth hormone >2.5 ng/ml: 120 mg once every 4 weeks.
120
mg
Subcutaneous (SC)
every 4 weeks
gastroenteropancreatic neuroendocrine tumors (GEP NET)
120
mg
Subcutaneous (SC)
every 4 weeks
No safe dosing is established
Refer to adult dosing
CYP3A Inhibitors: they may diminish the serum concentration of hormonal agents
CYP3A Inhibitors: they may diminish the serum concentration of hormonal agents
CYP3A Inhibitors: they may diminish the serum concentration of hormonal agents
CYP3A Inhibitors: they may diminish the serum concentration of hormonal agents
CYP3A Inhibitors: they may diminish the serum concentration of hormonal agents
indium In-111 capromab pendetide
may decrease the diagnostic effect when combined
when both drugs are combined may enhance the bradycardia effect and raise blood pressure
when both drugs are combined may enhance the bradycardia effect and raise blood pressure
when both drugs are combined may enhance the bradycardia effect and raise blood pressure
when both drugs are combined may enhance the bradycardia effect and raise blood pressure
when both drugs are combined may enhance the bradycardia effect and raise blood pressure
It may diminish the effects when combined with metformin by pharmacodynamic antagonism
lanreotide exerts its influence on gallium ga 68 dotatate by engaging in receptor binding competition, thereby diminishing its effects
It may diminish the effects when combined with copper CU 64 dotatate by the receptor binding mechanism
Frequency defined:
>10%:
Bradycardia
Headache
Rash at injection site
Weight loss
Diarrhea
Abdominal pain
Vomiting
Nausea
Flatulence
Anemia
Gallbladder sludge
Muscle pain
1%-10%
Sinus bradycardia
Dizziness
Loose stools
Constipation
Arthralgia
Muscle spasm
Dyspnea
<1%:
Abscess at the injection site
Anaphylaxis
Mitral valve insufficiency
Steatorrhea
Pregnancy consideration: insufficient information available regarding its effect on pregnancy to recommend its use.
Lactation: excretion of lanreotide in breast milk is not known.
Pregnancy category:
Patient information leaflet
Generic Name: Lanreotide
Pronounced: lan-ree-tide
Why do we use lanreotide?
Lanreotide is a somatostatin analog class of antineoplastic drug. It is used to treat Cushing’s disease, acromegaly, and neuroendocrine tumor of the gastrointestinal tract or the pancreas.